SLNO: the balance sheet

MyFinsight

For the quarter ending 2026-03-31, SLNO has $608,388K in assets. $112,588K in debts. $133,026K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
562.24%
Quick Ratio
532.43%
Cash Ratio
229.16%
Debt to Asset Ratio
18.51%
Unit: Thousand (K) dollars
Assets Breakdown
Long-term marketable securities
Cash and cash equivalents
Marketable securities
Others
Liabilities Breakdown
Additional paid-in-capital
Accumulated deficit
Long-term debt, net
Others

Balance Sheets	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Cash and cash equivalents	133,026	70,106	246,662	76,497
Marketable securities	122,573	235,366	252,272	210,344
Accounts receivable, net	47,139	28,208	25,506	24,624
Inventory, net	17,308	15,024	6,674	2,355
Prepaid expenses and other current assets	6,330	7,110	3,739	2,969
Total current assets	326,376	355,814	534,853	316,789
Property and equipment, gross	-	308	-	-
Less accumulated depreciation and amortization	-	123	-	-
Property and equipment, net	202	185	150	166
Operating lease right-of-use assets	3,891	2,191	2,314	2,434
Intangible assets, net	4,374	4,861	5,347	5,832
Long-term marketable securities	273,382	200,616	57,148	7,002
Other long-term assets	163	163	83	83
Total assets	608,388	563,830	599,895	332,306

Accrued interest payable	-	-	-	409
Accounts payable	12,386	12,435	8,145	6,216
Accrued compensation	5,723	9,677	7,248	6,267
Operating lease liabilities	1,163	726	697	676
Contingent liability for essentialis purchase price	13,846	20,327	-	-
Accrued clinical trial site costs	-	-	-	1,863
Other current liabilities	24,931	18,198	17,163	5,512
Total current liabilities	58,049	61,363	33,253	20,943
Contingent liability for essentialis purchase price	-	-	19,473	18,859
Long-term debt, net	49,871	49,863	49,854	49,845
Long-term lease liabilities	3,243	1,964	2,112	2,248
Other long-term liabilities	1,425	525	398	271
Total liabilities	112,588	113,715	105,090	92,166
Common stock, 0.001 par value, 100,000,000 shares authorized, 51,718,149 and 52,286,881 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively	52	52	54	50
Additional paid-in-capital	897,578	881,018	969,119	740,746
Accumulated other comprehensive income (loss)	-1,838	415	360	85
Accumulated deficit	-399,992	-431,370	-474,728	-500,741
Total stockholders equity	495,800	450,115	494,805	240,140
Total liabilities and stockholders equity	608,388	563,830	599,895	332,306

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

MyFinsight

Balance Sheets Overview

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Balance Sheets Overview

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Balance Sheets Overview

Current Ratio562.24%Quick Ratio532.43%Cash Ratio229.16%Debt to Asset Ratio18.51%Unit: Thousand (K) dollarsAssets BreakdownLong-term marketable securitiesCash and cash equivalentsMarketable securitiesOthersLiabilities BreakdownAdditional paid-in-capitalAccumulated deficitLong-term debt, netOthers

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Balance Sheets Overview

Current Ratio562.24%Quick Ratio532.43%Cash Ratio229.16%Debt to Asset Ratio18.51%Unit: Thousand (K) dollarsAssets BreakdownLong-term marketable securitiesCash and cash equivalentsMarketable securitiesOthersLiabilities BreakdownAdditional paid-in-capitalAccumulated deficitLong-term debt, netOthers

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets